



# Responding to non-communicable diseases during and beyond the COVID-19 pandemic

State of the evidence on COVID-19 and  
non-communicable diseases: a rapid review



WHO/2019-nCoV/Non-communicable\_diseases/Evidence/2020.1

© World Health Organization and the United Nations Development Programme, 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO or UNDP endorses any specific organization, products or services. The unauthorized use of the WHO or UNDP names or logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO) or the United Nations Development Programme (UNDP). Neither WHO nor UNDP are responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

**Suggested citation.** Responding to non-communicable diseases during and beyond the COVID-19 pandemic: State of the evidence on COVID-19 and non-communicable diseases: a rapid review. Geneva: World Health Organization and the United Nations Development Programme, 2020 (WHO/2019-nCoV/Non-communicable\_diseases/Evidence/2020.1). Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests and queries on rights and any other licensing arrangements, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO or UNDP concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO or UNDP in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO and UNDP to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO or UNDP be liable for damages arising from its use.

Graphic design by Zsuzsanna Schreck.

Front and back cover image: © CDC

## Summary

This document provides an initial review of emerging information (as of 2 July 2020) on the relations among COVID-19, NCDs and NCD risk factors. Peer-reviewed articles were retrieved from the NCBI PubMed, PMC and Google Scholar databases. The review demonstrates that people living with NCDs are at higher risk of severe COVID-19-related illness and death and that there are limited data for estimating risk. We also summarize the results of two WHO surveys that indicate that services for the prevention and treatment of NCDs have been severely disrupted since the pandemic began.

## Aims and objectives

To undertake an initial review of studies on the relations among COVID-19, NCDs and NCD risk factors.

## Methods

*Search.* A search for articles in NCBI PubMed, PMC and Google Scholar was undertaken between 18 May and 1 July 2020 with the keywords “COVID-19”, “coronavirus” and “SARS-CoV-2” in combination with any of the following: “(air) pollution”, “asthma”, “cancer”, “cardiovascular disease”, “chronic obstructive pulmonary disease”, “chronic respiratory disease”, “diabetes”, “diet”, “heart disease”, “hypertension”, “NCDs”, “noncommunicable disease”, “non-communicable diseases”, “obesity”, “overweight”, “physical activity”, “physical inactivity”, “smoking”, “smokers”, “tobacco” and “vaping”. No language filter was applied in the search. The references in the included articles were reviewed to establish accurate reporting.

*Study selection.* Publications of studies that assessed risk for hospitalization, severe or critical illness or death associated with NCDs or NCD risk factors and COVID-19 were included. Only peer-reviewed publications were used. The publications reported case-control, cross-sectional and descriptive studies, randomized and nonrandomized controlled trials, systematic reviews and meta-analyses.

Information on the continuity of health services during the COVID-19 pandemic (see below) was obtained from two surveys conducted by WHO during 2020.

## Limitations

This document is not a systematic review but rather an initial synthesis of emerging evidence, which continues to appear.<sup>1</sup> Meaningful risk estimates are still not available for many NCDs and NCD risk factors. Most of the peer-reviewed publications are from high- or upper-middle-income countries, and care must be taken in extrapolating the results to low- and middle-income countries. Factors that may influence COVID-19 outcomes other than NCDs (age, gender, ethnicity, mental health) are not addressed in this review.

---

<sup>1</sup> WHO is gathering the latest international scientific findings and knowledge on COVID-19 (1). The database, with other resources on COVID-19, represents a comprehensive multilingual source of current literature on the topic.

## Risk factors

### 1. Tobacco use

1.1 Tobacco is one of the main causes of premature mortality, killing more than eight million people a year globally; seven million deaths are due to direct tobacco use and 1.2 million to exposure to second-hand smoke (2). Tobacco use increases the risk of developing several NCDs, such as cardiovascular disease, chronic respiratory disease, diabetes and cancer (3). People living with pre-existing NCDs, including those caused by tobacco use, are more vulnerable to severe illness with COVID-19 (4).

1.2 The conclusion of a review of the evidence conducted by WHO up to 12 May 2020 suggested that smoking is associated with greater severity of disease and death in hospitalized COVID-19 patients. Although this is probably related to severity (5–7), evidence is now emerging that smokers may be at higher risk of hospitalization with COVID-19 (8–10). More generally, tobacco smoking is detrimental to the respiratory immune system and increases vulnerability to respiratory infectious diseases, including Middle East respiratory syndrome (11–13). Well-designed population-based studies are, however, necessary to address questions about hospitalization, COVID-19 severity, and the risk of infection by SARS-CoV-2<sup>2</sup> among smokers (14).

1.3 Cigarettes and other forms of tobacco use like water-pipes and smokeless tobacco, as well as e-cigarettes, may increase the risk of COVID-19, for example through hand-to-mouth contact (14).



---

2 'SARS-CoV-2' refers to the novel coronavirus, 'COVID-19' refers to SARS-CoV-2-associated disease.

## 2. Harmful use of alcohol

2.1 Harmful use of alcohol has negative effects on physical and mental health and is one of the leading risk factors for disease, disability and death globally. It is causally linked to more than 200 codes for diseases and injury in the International Classification of Diseases (10th revision), including NCDs such as cancer, stroke and hypertension (15).

2.2 To date, few studies have been performed to quantify the effect of alcohol consumption on vulnerability to COVID-19. Use of alcohol is nevertheless associated with significant health risks and can lead to the development of substance use disorders and other health conditions due to intoxication, toxicity or other long-lasting effects. Harmful use of alcohol and other psychoactive substances has a number of negative effects, which include undermining immune function, thus weakening the body's ability to fight SARS-CoV-2 infection. Even a single session of heavy alcohol use can have measurable negative effects on both adaptive and innate immune responses (16). Harmful use of alcohol also increases the risk of diseases associated with severe COVID-19 (16–19). Scientific evidence refutes the suggestion that alcohol can protect against COVID-19 (20).

2.3 Alcohol use not only impairs overall physiological and immune function but can have other negative effects during the COVID-19 pandemic (21). Unhealthy behaviour such as harmful use of alcohol may increase during challenging times as a coping strategy to relieve stress or anxiety or to pass time when self-isolating (22). Harmful alcohol use affects psychological well-being and can impair judgement, self-regulation, motor coordination and reaction time. This in turn increases the risks of injuries and violence, including intimate partner violence, which is being exacerbated by the pandemic (23, 24). Moreover, harmful use of alcohol interferes with people's ability to take precautions to protect themselves against infection, such as compliance with hand hygiene, and can decrease the effectiveness of COVID-19 protective measures by interfering with compliance with regulatory and treatment regimens (25).

2.4 People with alcohol use disorder may be more vulnerable to COVID-19 (26) and may be at particular risk of acquiring a range of infections due to risk factors associated with alcohol use, such as sharing objects (bottles and other containers, tableware), gathering in groups, poverty, unemployment, worse physical health and a greater likelihood of arrest and incarceration. In global humanitarian settings, people with substance use disorders are often already marginalized and may not have appropriate treatment options. During a pandemic, these populations may be particularly vulnerable and neglected and should therefore be considered in mental health and psychosocial support responses.



### 3. Physical inactivity

3.1 Physical inactivity is one of the main risk factors for developing NCDs, while regular physical activity helps to prevent risk factors such as hypertension, overweight and obesity, protects against NCDs and contributes importantly to improving mental health (27, 28).


3.2 Physical inactivity may indirectly influence the progression of COVID-19 disease. A large-scale study of behavioural risk factors for COVID-19 suggests that physical inactivity is a risk factor for hospitalization related to the disease (9). Physical inactivity is associated with obesity, a metabolic risk factor for severe COVID-19 disease (29, 30). In contrast, physical activity can stimulate immune function and reduce inflammation and also has various physiological and psychological benefits, including reducing stress and anxiety (28, 31, 32). Insufficient physical activity and sedentary behaviour, including a sedentary work culture, are exacerbated by pandemic-related lockdowns and travel restrictions, increasing the associated risk for obesity or NCDs (33, 34). Therefore, maintaining regular physical activity is especially important during the pandemic and extended time at home (35).

### 4. Malnutrition and unhealthy diets

4.1 Globally, malnutrition in all its forms (including undernutrition, micronutrient deficiencies, overweight and obesity) is a leading cause of disease and NCD-related mortality (36). Malnutrition throughout the life course exacerbates the risk of NCDs: both childhood undernutrition and obesity are associated with increased likelihoods of adult obesity and NCD onset (37).

4.2 Overweight and obesity are among the most common comorbid conditions in hospitalized COVID-19 patients and have been associated with higher risks of adverse outcomes (30, 38). A higher likelihood of severe COVID-19 is in accordance with previous findings that obesity is pro-inflammatory, impairs immune responses to viral infection, induces diabetes and oxidant stress and restricts both cardiovascular and respiratory function (39, 40). While it is clear that obese patients are more vulnerable to COVID-19 (41), limitations in study size and lack of comprehensive documentation of patients' body mass indices currently obviate statistically powerful analyses to estimate relative risks accurately (42–45).

4.3 Obesity has been highlighted as a risk factor for severe COVID-19 in several studies (44, 46). First, obesity is one of the most prevalent pre-existing medical conditions in hospitalized patients in the USA (38, 47). Secondly, obese males were more likely to develop severe pneumonia than patients of normal weight (odds ratio [OR], 5.7; 95% confidence interval [CI], 1.8;17.8) (29). Thirdly, in a study involving 124 patients admitted to intensive care units, disease severity increased with body mass index even after adjustment for potential confounding factors such as age, diabetes and hypertension. The risk of severe COVID-19 was markedly increased in the severely obese group (body mass index > 35) (OR, 7.36; 95% CI, 1.63;33.14) (30).



A nationwide study of 177,000 people in Mexico found that obesity was a risk factor for both admission to intensive care and mortality from COVID-19 (hazard ratio, 1.25; 95% CI, 1.17;1.34) (48). Overweight has also been associated with adverse outcomes from COVID-19. A study of 112 intensive care patients found that the percentage of overweight patients (body mass index  $\geq 25$ ) was much higher among non-survivors (88% overweight) than among survivors (19% overweight) (49).

4.4 Unhealthy diets, including those low in fruits and vegetables, high in sodium and sugar, low in nuts and seeds, low in whole grains, and low in seafood-derived omega-3 fatty acids, cause NCDs (50). While empirical evidence remains limited, many indicators suggest a negative impact of the COVID-19 pandemic on dietary patterns, subsequently increasing long-term NCD risk. Examples include the early trend of stockpiling processed shelf-stable food, which may lead to overconsumption; widespread job losses and financial hardship, limiting the affordability of the safe, diverse, nutritious foods that contribute to healthy diets; and supply chain disruptions or containment measures that affect the accessibility of nutritious perishable foods (including fruit, vegetables and fresh fish) (51). A survey of Italian adults under lockdown restrictions found that consumption of nutritious foods increased but so also did intake of sweets, and 49% of respondents reported weight gain since the lockdown (52). An investigation in Portugal indicates that worsening of dietary behaviour during COVID-19 is most prevalent in low socioeconomic communities, with an increase in the intake of snack foods, ready meals, sugar-sweetened beverages and takeaways (53), whereas high socioeconomic groups improved their dietary intake, with increased intake of fruits, vegetables and other nutrient-dense foods. This suggests that COVID-19 is likely to widen socioeconomic inequalities in dietary quality.

4.5 Good nutrition supports a strong immune system. For instance, fruit and vegetables provide vitamins and minerals, and healthy fats in olives or seeds are rich in unsaturated fatty acids, which are necessary for a functioning immune response (54). In contrast, a diet rich in saturated fats, sugar and salt predisposes to obesity, diabetes, hypertension and cancer, which have been linked to more severe COVID-19 infection (see following sections) (55, 56). Furthermore, the so-called “western” diet (high in fats, sugar and carbohydrates) leads to chronic inflammation and impaired immune response to viral infections (57).

## 5. Environmental risks

5.1 Household and outdoor air pollution are major causes of death from NCDs. Exposure to air pollution in general and especially to high levels of particulate matter have been associated mainly with the development of lung cancer, chronic obstructive pulmonary disease and cardiovascular disease (58).

5.2 Further research is required on the potential links between exposure to higher concentrations of air pollutants, exacerbation of symptoms in people infected with COVID-19 and the potential consequences for those who are treated (59). Fine particles induce an inflammatory response and impair (respiratory) immune function, and long-term exposure to pollution and associated inflammation is known to damage the lungs and heart, potentially leading to comorbid conditions (60), which may decrease the ability of exposed individuals to fight SARS-CoV-2.

5.3 Exposure to air pollution probably influences mortality due to COVID-19, but further studies should be conducted. Several studies in which mortality from COVID-19 was associated with levels of air pollution have been published only as non-peer-reviewed preprints and were therefore not included in this review. Nonetheless, the risk of death was suggested to increase with short-term exposure to elevated concentrations of pollutants (NO<sub>2</sub> and PM<sub>2.5</sub>) in a small study in the United Kingdom (61). These findings are corroborated by those of another study, in which the majority of deaths (78% of 4,443 fatalities) investigated in Europe occurred in five regions characterized by high pollution levels and geographical settings that prevent dispersal of airborne pollutants (62). During the SARS epidemic of 2002, air pollution was also correlated with fatality rates (63).

5.4 Household air pollution (e.g. from use of solid fuels and kerosene for cooking) and second-hand tobacco smoke also impair lung and immune functions and probably increase the risk for adverse effects of COVID-19 (64, 65).

## Diseases

### 6. Diabetes

6.1 Diabetes affects over 500 million people worldwide, and its prevalence and the premature mortality it causes are rapidly rising. Diabetes is also a major cause of disability, cardiovascular disease and kidney failure (66).

6.2 People with diabetes are at increased risk for hospitalization and adverse events after SARS-CoV-2 infection (67–70). A systematic review of studies with a total of 1382 patients indicated that people with diabetes were at increased risk of admission to intensive care (OR, 2.79; 95% CI, 1.85;4.22) and mortality (OR, 3.21; 95% CI, 1.82;5.64) (69). Their increased vulnerability may be explained by presence of comorbid conditions, including cardiovascular disease (67), and impaired immune response to infection (71).

6.3 People with uncontrolled diabetes are even more vulnerable to poor outcomes after COVID-19 infection. A large cohort study of 17 million patients in the United Kingdom indicated that those with uncontrolled diabetes had a higher risk of dying from COVID-19 than either non-diabetics or people with controlled diabetes (72). An increased risk was observable even after adjustment for a variety of confounding factors. This conclusion is supported by the well-documented association between poor glycaemic control and impaired immune function (73).

6.4 The significant vulnerability of patients with uncontrolled diabetes is of particular concern, as nearly half of all cases of adult diabetes globally are estimated to be undiagnosed (74). Achievement and maintenance of glycaemic control are imperative for all diabetes patients, especially during the COVID-19 pandemic. Limited access of patients with diagnosed diabetes to health care services and medication, economic instability, unstable food intake and/or active infection with COVID-19 complicate or even preclude adequate glycaemic control. People living with diabetes are therefore one of the groups most vulnerable to the pandemic.

## 7. Cardiovascular diseases

7.1 Cardiovascular diseases, in particular heart attacks and strokes, are the most common cause of death globally. In 2016, an estimated 17.9 million people died from these diseases, comprising 31% of all deaths. Most cardiovascular diseases are preventable and are associated with risk factors such as tobacco use, harmful use of alcohol, an unhealthy diet and physical inactivity (75).

7.2 Cardiovascular diseases are associated with increased risks for severe COVID-19 and mortality. Hypertension has been identified as a risk factor for worse outcomes after SARS-CoV-2 infection (7, 76). In a meta-analysis of 12 studies, hypertension was a risk factor for both disease severity (OR, 2.27; 95% CI, 1.80;2.86) and mortality (OR, 3.48; 95% CI, 1.8;2.86) (77). In contrast, a large cohort study of 17 million United Kingdom citizens did not indicate that hypertension was a risk factor for COVID-19 mortality after adjustment for several covariates (72). Hypertension is highly prevalent throughout the world, with a large group of people at risk. While several hypotheses have been suggested, the mechanism by which people with hypertension become more vulnerable remains unclear. Additional large, randomized, well-characterized studies are necessary, with consideration of possible confounding factors, including age and multiple morbid conditions (78).



7.3 Other cardiovascular diseases, including heart failure, coronary artery disease and cardiac arrhythmia, increase the odds of death from SARS-CoV-2 infection by at least twice (72, 79–82). Other studies and meta-analyses also indicate higher risks of adverse outcomes for patients with cardiac injury, a common symptom in many patients with cardiovascular disease, including those with a history of stroke (83, 84).

## 8. Chronic respiratory diseases

8.1 Chronic respiratory conditions are major NCDs and were responsible for 8% of NCD-related deaths in 2012 (85). Most deaths are from two of the main respiratory conditions, chronic obstructive pulmonary disease (COPD) and asthma, and occur mainly in low- and middle-income countries (86, 87). Major risk factors for chronic respiratory diseases are exposure to air pollution and tobacco use (88).

8.2 WHO has classified all patients with chronic respiratory diseases as especially vulnerable to COVID-19 (4). Given that many respiratory viruses worsen the condition of patients with chronic airway diseases (89), all affected individuals should be extremely cautious with regard to SARS-CoV-2. In a meta-analysis of 15 studies, patients with COPD were found to be at higher risk for severe COVID-19 disease (relative risk, 1.88; 95% CI, 1.4;2.4) and have a higher mortality rate than those without COPD (5). While patients with COPD have been shown to be vulnerable to COVID-19, how it interacts with other chronic respiratory diseases is yet to be ascertained.

8.3 The vulnerability of asthma patients to COVID-19 is currently unknown. One large observational cohort study (20,133 cases of COVID-19) suggested that people with asthma were not at increased risk for mortality but were overrepresented among hospitalized COVID-19 patients (90). Another large study (17.4 million adults) suggested that asthma is a risk factor for mortality (hazard ratio, 1.25; 95% CI, 1.08;1.44) (72). A third study suggested that asthma patients (including 72,314 COVID-19 cases) had no increased risk of infection, disease severity or mortality (91). One study even suggested that patients with allergic asthma were at lower risk of infection and severe disease (92). The variation among the results may be due to insufficient stratification of patients with regard to the type, management and treatment of asthma (93). Further studies are required to understand the relation between COVID-19 and asthma.

8.4 Information on vulnerability to COVID-19 among people with other chronic lung diseases, such as cystic fibrosis, bronchiectasis and interstitial lung diseases, is too limited to form the basis for risk estimates. Nonetheless, two large studies found that “non-asthmatic respiratory disease” (which includes COPD) was a risk factor for mortality from COVID-19 (72, 91). Inflammation and scarring of lung tissue associated with chronic disease increase vulnerability to several respiratory viruses; however, not all viruses affect patients with chronic lung diseases in the same way (94). An important consideration is that the common symptoms of COVID-19 are similar to those of many chronic respiratory diseases, which may delay or impair diagnosis of COVID-19 disease in patients with other diseases. The similarity of symptoms may have severe consequences for those affected and potentially confound studies. Therefore, regular check-ups for patients with chronic lung diseases should be safely maintained, and further studies should be conducted to improve understanding of how SARS-CoV-2 infection and the range of chronic respiratory diseases interact.

## 9. Cancer

9.1 Globally, cancer is the second leading cause of death, and, of the nearly 10 million cancer-related deaths in 2018, most occurred in low- and middle-income countries. About one third of cancer deaths can be attributed to preventable risk factors such as overweight, obesity, an unhealthy diet, physical inactivity, use of tobacco and use of alcohol (95).

9.2 Cancer has been reported to be a risk factor for COVID-19 infection, severity and mortality. An increased likelihood of SARS-CoV-2 infection may be explained by malignant interference with immune function or other physiological disturbance (96). People living with cancer were also reported to be more likely to experience severe symptoms or die from COVID-19 infection (72). Patients who are at particular risk are those with current or recent haematological malignancies, advanced metastatic disease or profound immunosuppression, e.g. patients undergoing active chemotherapy or those who have undergone bone marrow transplantation or surgery (97, 98).

9.3 People with malignancies are more vulnerable to COVID-19. Those with a history of cancer have been shown to be overrepresented not only among SARS-CoV-2-positive individuals overall but also among those experiencing progression of severe disease (99). A multicentre study in China showed that cancer patients have increased odds of severe COVID-19 illness (OR, 3.61; 95% CI, 2.59;5.04) (100). History of cancer was further determined to increase the risk of death from COVID-19 in a propensity-score matched analysis normalising for patient age

(OR, 2.98; 95% CI, 1.76;5.06) (101). Similarly, a study of 17.4 million adults in the United Kingdom found that a history of non-haematological cancer diagnosed < 1 year previously was an independent risk factor for mortality from COVID-19, even after adjustment for patients' age, sex and other comorbid conditions (hazard ratio, 1.25; 95% CI, 1.29;1.89) (72).

9.4 Additional data are required to understand the exact association between cancer and vulnerability to COVID-19. Several of the studies on cancer and COVID-19 have important limitations. For example, as studies suggest that mortality from COVID-19 is skewed towards late-stage cancer patients, the increased likelihood of death might be due to inherently worse overall health rather than to COVID-19-specific effects (98, 102).

<b>Italy</b>	68% of people who died of COVID-19 in hospitals had hypertension, and 31% had type 2 diabetes.
<b>India</b>	30% fewer cardiac emergencies reached health facilities in rural areas in March 2020 than in March 2019.
<b>Netherlands</b>	The number of new diagnoses of cancer decreased by 25% as a result of the lockdown.
<b>Spain</b>	43% of patients with severe COVID-19 disease had cardiovascular diseases.
<b>Globally</b>	75% of participating countries reported complete or partial disruption of NCD management services, including rehabilitation, asthma care, cancer treatment and cardiovascular emergency services.

Rapid assessment of service delivery for NCDs during the COVID-19 pandemic (108)

## Pandemic-related disruption of prevention and treatment services for NCDs

10.1 While people living with NCDs are more vulnerable to COVID-19, services for the prevention and treatment of NCDs are also negatively affected by the pandemic. Travel constraints and lockdowns limit access to preventive services, hospital treatment and prescription medicines (103).

10.2 Health systems around the world are being challenged by increasing demand for care of people with COVID-19, compounded by fear, stigmatization, misinformation and limitations on movement that disrupt the delivery of care for all health conditions. When health systems are overwhelmed and people cannot access the care they need, both direct mortality from the outbreak and indirect mortality from preventable and treatable conditions increase dramatically (104–106). As demands on systems surge and health workers themselves are increasingly affected by COVID-19 infection, countries and health care workers have had to make difficult decisions to balance the demands of responding directly to the COVID-19 pandemic with maintaining the delivery of other essential health services. Establishing a safe, effective patient flow (including screening for COVID-19, triage and targeted referral) remains critical at all levels. Many routine and elective services have been suspended, and delivery approaches are being adapted to the evolving pandemic context as the risk–benefit analysis for any given activity changes (107, 108).

## Rapid assessment of service delivery for NCDs

10.3 Between 15 May 2020 and 29 July 2020, WHO conducted a rapid assessment of the continuity of essential health services during the COVID-19 pandemic (109). Responses from 105 Member States (from 5 regions) demonstrated that over half have limited or suspended outpatient and community-based services. Globally, NCD diagnosis and treatment services were among the five most frequently interrupted services. More than half of countries reported disruptions in the service areas related to the diagnosis and treatment of NCDs, mental health disorders, and cancer.

The main reasons for disruptions to the delivery and use of essential health services overall were:

- a decrease in outpatient volume due to non-presentation of patients;
- a decrease in inpatient volume because of cancellation of elective care;
- related clinical staff deployed to provide COVID-19 relief;
- limited access due to government or public transport lockdowns;
- insufficient personal protective equipment for health care providers; and
- closure of services, such as population-level screening programmes, and outpatient clinics

10.4 In the WHO African Region, the most commonly reported disruptions were outreach immunization services, family planning, contraception and antenatal care. In the Eastern Mediterranean Region, rehabilitation and palliative care services were disrupted in all countries. In Europe, rehabilitation, NCD diagnosis and treatment and family planning services were the most commonly discontinued. In the South-East Asia Region, the most commonly disrupted services included NCD diagnosis and treatment, while in the Western Pacific Region outreach immunization services were not functioning or were functioning at limited capacity. Globally, NCD diagnosis and treatment services were among the five most frequently interrupted services (109).

10.5 Before the pandemic, most communities in the world and particularly many settings with humanitarian crises or conflict already had limited access to good-quality, affordable NCD diagnosis and care (107). Their access has now been reduced further, as the COVID-19 pandemic has disrupted services.

## Rapid assessment of continuity of essential health services

10.6 Between 1 and 25 May 2020, WHO conducted a rapid assessment survey of service delivery for NCDs during the COVID-19 pandemic among 194 ministries of health (107). Responses were received from 163 ministries (84%).

- 122 of 163 countries (75%) reported disruption of NCD services.
- The more severe the transmission phase of the COVID-19 pandemic, the more NCD services were disrupted. For example, the proportions of countries with disrupted services for hypertension management were 39% for sporadic cases, 57% for cluster transmission and 66% for community transmission.

- The most common reasons for discontinuing or reducing services were cancellations of planned treatments, less public transport available and lack of staff because health workers had been reassigned to COVID-19 services. In 20% of the countries that reported disruptions, some of the main reasons for discontinuing services were shortages of medicines, diagnostics and other technologies. In most countries, however, alternative strategies had been established to ensure that people at highest risk of COVID-19 continued to receive treatment for NCDs.
- Closure of population-level screening programmes (for example for breast and cervical cancer) was reported by 46% of countries. This was consistent with initial WHO recommendations to minimize non-urgent facility-based care while tackling the pandemic.
- Telemedicine and triaging were the mitigation strategies most often used to overcome disruption. Among the countries that reported service disruptions, 58% are now using telemedicine (advice by telephone or online) to replace in-person consultations; in low-income countries, the figure was 42%.
- 17% of countries allocated additional funding from government budgets to include the provision of NCD services in the national COVID-19 plan.
- 66% of the countries have included the continuity of NCD services in national COVID-19 plans. Most countries that have included NCD services in their national COVID-19 plan have prioritized services for the four major NCDs – cancer, cardiovascular disease, chronic respiratory disease and diabetes.

## References

1. Global research on coronavirus disease (COVID-19). Geneva: World Health Organization; 2020 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov>).
2. WHO report on the global tobacco epidemic 2019. Geneva: World Health Organization; 2019 ([https://www.who.int/tobacco/global\\_report/en/](https://www.who.int/tobacco/global_report/en/), accessed 21 July 2020).
3. Executive summary. The health consequences of smoking – 50 years of progress: a report of the Surgeon General. Atlanta (GA): Department of Health and Human Services; 2014.
4. Information note on COVID-19 and NCDs. Geneva: World Health Organization; 2020 (<https://www.who.int/who-documents-detail/covid-19-and-ncds>, accessed 12 May 2020).
5. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almeahmadi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. *PLoS One*. 2020;15(5):e0233147.
6. Li J, He X, Yuan Y, Zhang W, Li X, Zhang Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. *Am J Infect Control*. 2020. doi:10.1016/j.ajic.2020.06.008.
7. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. *J Infect*. 2020; 81(2):e16–25.
8. Killerby ME, Link-Gelles R, Haight SC, Schrodt CA, England L, Gomes DJ, et al. Characteristics associated with hospitalization among patients with COVID-19 – metropolitan Atlanta, Georgia, March–April 2020. *Morbidity and Mortality Weekly Report*. 2020;69(25):790–4.
9. Hamer M, Kivimäki M, Gale CR, David Batty G. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based cohort study of 387,109 adults in UK. *Brain Behav Immun*. 2020;87:184.
10. Soares R de CM, Mattos LR, Raposo LM. Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo State, Brazil. *Am J Trop Med Hyg*. 2020. doi:10.4269/ajtmh.20-0483.
11. Tonnesen P, Marott JL, Nordestgaard B, Bojesen SE, Lange P. Secular trends in smoking in relation to prevalent and incident smoking-related disease: a prospective population-based study. *Tob Induc Dis*. 2019;17:72.
12. Zhou Z, Chen P, Peng H. Are healthy smokers really healthy? *Tob Induc Dis*. 2016;14(1):1–12.
13. Arcavi L, Benowitz NL. Cigarette smoking and infection. *Arch Intern Med*. 2004;164(20):2206–16.
14. Smoking and COVID-19: WHO scientific brief, 30 June 2020. Geneva: World Health Organization; 2020 (<https://apps.who.int/iris/handle/10665/332895>).
15. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018 ([https://www.who.int/substance\\_abuse/publications/global\\_alcohol\\_report/en/](https://www.who.int/substance_abuse/publications/global_alcohol_report/en/), accessed 22 July 2020).
16. Szabo G, Saha B. Alcohol's effect on host defense. *Alcohol Res*. 2015;37(2):159.
17. Sarkar D, Jung MK, Wang HJ. Alcohol and the immune system. *Alcohol Res*. 2015;37(2):153–5.
18. Ferreira-Borges C, Breda J NM. Alcohol and COVID-19: what you need to know. Copenhagen: World Health Organization Regional Office for Europe; 2020 ([http://www.euro.who.int/\\_data/assets/pdf\\_file/0010/437608/Alcohol-and-COVID-19-what-you-need-to-know.pdf](http://www.euro.who.int/_data/assets/pdf_file/0010/437608/Alcohol-and-COVID-19-what-you-need-to-know.pdf), accessed 29 April 2020).

19. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020. *Morbidity and Mortality Weekly Report*. 2020;69(13):382–6.
20. Alcohol use – Alcohol does not protect against COVID-19; access should be restricted during lockdown. Copenhagen: World Health Organization Regional Office for Europe; 2020 ([http://www.euro.who.int/en/health-topics/disease-prevention/alcohol-use/news/news/2020/04/alcohol-does-not-protect-against-covid-19-access-should-be-restricted-during-lockdown/\\_cache?fbclid=IwAR2IkIQcxfDdziOa7esAbXO-calV66wvhmP4JxoDwXQd5z14X02jAmHZulg](http://www.euro.who.int/en/health-topics/disease-prevention/alcohol-use/news/news/2020/04/alcohol-does-not-protect-against-covid-19-access-should-be-restricted-during-lockdown/_cache?fbclid=IwAR2IkIQcxfDdziOa7esAbXO-calV66wvhmP4JxoDwXQd5z14X02jAmHZulg), accessed 10 May 2020).
21. Drinking alone: COVID-19, lockdown, and alcohol-related harm. *Lancet Gastroenterology and Hepatology*. 2020;5:625.
22. Clay JM, Parker MO. Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? *Lancet Public Health*. 2020;5:e259.
23. Women’s Safety NSW, Foundation for Alcohol Research and Education. Family violence and alcohol during COVID-19. Sydney: Foundation for Alcohol Research and Education; 2020 (<https://movendi.ngo/news/2020/06/03/covid-19-australia-alcohols-role-in-family-violence-revealed/>, accessed 19 June 2020).
24. Matzopoulos R, Walls H, Cook S, London L. South Africa’s COVID-19 alcohol sales ban: the potential for better policy-making. *International Journal of Health Policy Management*. 2020;2020:1–2.
25. Sansone RA, Sansone LA. Alcohol/Substance misuse and treatment nonadherence: fatal attraction. *Psychiatry (Edgmont)*. 2008 Sep;5(9):43-6.
26. Da BL, Im GY, Schiano TD. COVID-19 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease. *Hepatology*. 2020. doi:10.1002/hep.31307.
27. Physical inactivity: a global public health problem. Geneva: World Health Organization; 2018 (<https://www.who.int/ncds/prevention/physical-activity/inactivity-global-health-problem/en/>, accessed 16 July 2020).
28. Global recommendations on physical activity for health. Geneva: World Health Organization; 2015. (<https://www.who.int/dietphysicalactivity/publications/9789241599979/en/>).
29. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. *Diabetes Care*. 2020;43(7):1392–8.
30. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity*. 2020;28(7): doi:10.1002/oby.22831.
31. Nieman DC, Wentz LM. The compelling link between physical activity and the body’s defense system. *J Sport Health Sci*. 2019;8(3):201–17.
32. Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. *British Journal of Sports Medicine*. 2014;48(3):187–96.
33. Ricci F, Izzicupo P, Moscucci F, Sciomer S, Maffei S, Di Balassare A, et al. Recommendations for physical inactivity and sedentary behavior during the coronavirus disease (COVID-19) pandemic. *Frontiers in Public Health*. 2020;8:199.
34. Narici M, De Vito G, Franchi M, Moro T, Marcolin G, Grassi B, et al. Impact of sedentarism due to the COVID-19 home confinement on neuromuscular, cardiovascular and metabolic health: physiological and pathophysiological implications and recommendations for physical and nutritional countermeasures. *European Journal of Sport Science*. 2020;1–22. doi:10.1080/17461391.2020.176106.
35. Chen P, Mao L, Nassis GP, Harmer P, Ainsworth BE, Li F. Wuhan coronavirus (2019-nCoV): The need to maintain regular physical activity while taking precautions. *J Sport Health Sci*. 2020;9(2):103–4.
36. 2020 Global Nutrition Report. Action on equity to end malnutrition. Executive summary. Bristol: Development Initiatives Poverty Research Ltd; 2020 (<https://globalnutritionreport.org/reports/2020-global-nutrition-report/executive-summary/>, accessed 19 June 2020).

37. UNSCN brief: “Non-communicable diseases, diets and nutrition”. Rome: United Nations System Standing Committee on Nutrition; 2018 (<https://www.unscn.org/en/unscn-publications?idnews=1831>, accessed 19 June 2020).
38. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 states, March 1–30, 2020. *Morbidity and Mortality Weekly Report*. 2020;69(15):458–64.
39. The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med*. 2017;377(1):13–27.
40. Honce R, Schultz-Cherry S. Impact of obesity on influenza A virus pathogenesis, immune response, and evolution. *Front Immunol*. 2019;10(5):1071.
41. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: a systematic review and meta-analysis. *J Med Virol*. 2020. doi:10.1002/jmv.26237.
42. Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. *Clin Obesity*. 2020. doi:10.1111/cob.12365.
43. Acharya P, Upadhyay L, Qavi A, Naaraayan A, Jesmajian S, Acharya S, et al. The paradox prevails: Outcomes are better in critically ill obese patients regardless of the comorbidity burden. *J Crit Care*. 2019;53:25–31.
44. Buscemi S, Buscemi C, Batsis JA. There is a relationship between obesity and COVID-19 but more information is needed. *Obesity*. 2020. doi:10.1002/oby.22883.
45. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. *Nat Rev Endocrinol*. 2020;16:341–2.
46. Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Obesity – a risk factor for increased COVID-19 prevalence, severity and lethality (review). *Mol Med Rep*. 2020. doi:10.3892/mmr.2020.11127.
47. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ*. 2020;369:m1966.
48. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. *J Clin Endocrinol Metab*. 2020;105(8):dgaa346.
49. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV (in Chinese). *Zhonghua Xin Xue Guan Bing Za Zhi*. 2020;48:E004.
50. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2019;393(10184):1958–72.
51. COVID-19 and the risk to food supply chains: How to respond. Rome: Food and Agriculture Organization of the United Nations; 2020. (<http://www.fao.org/3/ca8388en/CA8388EN.pdf>).
52. Di Renzo L, Gualtieri P, Pivari F, Soldati L, Attinà A, Cinelli G, et al. Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey. *J Transl Med*. 2020;18(1):229.
53. Inquérito sobre alimentação e atividade física em contexto de contenção social [Survey on food and physical activity in the context of social containment]. Lisbon: Directorate-General of Health; 2020 (<https://www.dgs.pt/documentos-e-publicacoes/inquerito-sobre-alimentacao-e-atividade-fisica-em-contexto-de-contencao-social.aspx>, accessed 13 July 2020).
54. Maintaining a healthy diet during the COVID-19 pandemic. Rome: Food and Agriculture Organization of the United Nations; 2020. doi:10.4060/ca8380en.
55. Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: a systematic review. *Diabetes Metab Syndr Clin Res Rev*. 2020;14(4):655–9.

56. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes Metab Syndr Clin Res Rev.* 2020;14(4):535–45.
57. Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. *Brain Behav Immun.* 2020;87:53–4.
58. Prüss-Ustün A, Van Deventer E, Mudu P, Campbell-Ledndrum D, Vickers C, Ivanov I, et al. Environmental risks and non-communicable diseases. *BMJ.* 2019;364:l265.
59. Liang D, Shi L, Zhao J, Liu P, Schwartz J, Gao S, et al. Urban air pollution may enhance COVID-19 case-fatality and mortality rates in the United States. *medRxiv.* 2020:2020.05.04.20090746.
60. Colaço M, Duarte A, Zuzarte M, Costa BFO, Borges O. Airborne environmental fine particles induce intense inflammatory response regardless of the absence of heavy metal elements. *Ecotoxicol Environ Saf.* 2020;195:110500.
61. Sasidharan M, Singh A, Torbaghan ME, Parlikad AK. A vulnerability-based approach to human-mobility reduction for countering COVID-19 transmission in London while considering local air quality. *Sci Total Environ.* 2020;741:140515.
62. Ogen Y. Assessing nitrogen dioxide (NO<sub>2</sub>) levels as a contributing factor to coronavirus (COVID-19) fatality. *Sci Total Environ.* 2020;726:138605.
63. Cui Y, Zhang Z-F, Froines J, Zhao J, Wang H, Yu S, et al. Air pollution and case fatality of SARS in the People's Republic of China: an ecologic study. *Environ Health.* 2003;2(1):1–5.
64. Alnahari S, Halliday D, Gonzalez M-E, Garcia-Ojeda M, Song A. Tobacco control is a critical response to COVID-19 management. *Coronavirus (COVID-19) report April 2020.* Merced (CA): University of California Merced, Nicotine & Cannabis Policy Center; 2020 ([https://ncpc.ucmerced.edu/sites/ncpc.ucmerced.edu/files/page/documents/ncpc\\_covid\\_report3\\_-\\_april\\_2020.pdf](https://ncpc.ucmerced.edu/sites/ncpc.ucmerced.edu/files/page/documents/ncpc_covid_report3_-_april_2020.pdf), accessed 13 May 2020).
65. Household air pollution and health. Geneva: World Health Organization; 2020 (<https://www.who.int/news-room/fact-sheets/detail/household-air-pollution-and-health>, accessed 13 May 2020).
66. Diabetes. Fact sheets. Geneva: World Health Organization; 2020 (<https://www.who.int/news-room/fact-sheets/detail/diabetes>, accessed 16 July 2020).
67. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol Metab.* 2020;318(5):E736–41.
68. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA.* 2020;323(20):2052–9.
69. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. *J Clin Virol.* 2020;127:104354.
70. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. *Aging Male.* 2020:1-9.
71. Ferlita S, Yegiazaryan A, Noori N, Lal G, Nguyen T, To K, et al. Type 2 diabetes mellitus and altered immune system leading to susceptibility to pathogens, especially *Mycobacterium tuberculosis*. *J Clin Med.* 2019;8(12):2219.
72. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. *Nature.* 2020. doi:10.1038/s41586-020-2521-4.
73. Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. *Diabetes Care.* 2018;41(10):2127–35.

74. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. *Diabetes Res Clin Pract.* 2014;103(2):150–60.
75. Cardiovascular diseases (CVDs). Fact sheets. Geneva: World Health Organization; 2020 ([https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))), accessed July 16, 2020.
76. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. *Int J Infect Dis.* 2020;94:91–5.
77. Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W, et al. Associations of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-Analysis. *Epidemiol Infect.* 2020;148:e106.
78. Drager LF, Pio-Abreu A, Lopes RD, Bortolotto LA. Is hypertension a real risk factor for poor prognosis in the COVID-19 pandemic? *Curr Hypertens Rep.* 2020;22(6):43.
79. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. *Eur Respir J.* 2020. doi:10.1183/13993003.00547-2020.
80. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. *J Med Virol.* 2020. doi:10.1002/jmv.26050.
81. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with covid-19: Evidence from meta-analysis. *Aging (Albany NY).* 2020;12(7):6049–57.
82. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bioni-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. *J Am Coll Cardiol.* 2020;75(18):2352–71.
83. Toraih EA, Elshazli RM, Hussein MH, Elgami A, Amin M, El-Mowafy M, et al. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: a meta-regression and decision tree analysis. *J Med Virol.* 2020;jmv.26166.
84. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol.* 2020;5(7):802–10.
85. Global status report on noncommunicable diseases 2014. Attaining the nine global noncommunicable diseases targets; a shared responsibility. Geneva: World Health Organization; 2014 ([https://apps.who.int/iris/bitstream/handle/10665/148114/9789241564854\\_eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/148114/9789241564854_eng.pdf?sequence=1), accessed August 2020).
86. Asthma. Fact sheets. Geneva: World Health Organization; 2020 (<https://www.who.int/news-room/fact-sheets/detail/asthma>, accessed 16 July 2020).
87. Chronic obstructive pulmonary disease (COPD). Fact sheets. Geneva: World Health Organization; 2020 ([https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd))), accessed 16 July 2020).
88. Risk factors for chronic respiratory diseases. In: GARD Book Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. ISBN 978 92 4 156346 8 (NLM Classification. WF140). Geneva: World Health Organization; 2017 (<https://www.who.int/gard/publications/Risk%20factors.pdf>).
89. Britto CJ, Brady V, Lee S, Dela Cruz CS. Respiratory viral infections in chronic lung diseases. *Clin Chest Med.* 2017;38(1):87–96.
90. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ.* 2020;369:m1985.
91. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA.* 2020;323(13):1239–42.

92. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol*. 2020;146(1):202–6.
93. Liu S, Zhi Y, Ying S. COVID-19 and asthma: reflection during the pandemic. *Clin Rev Allergy Immunol*. 2020;59:78–88.
94. Morais-Almeida M, Pité H, Aguiar R, Ansotegui I, Bousquet J. Asthma and the coronavirus disease 2019 pandemic: a literature review. *Int Arch Allergy Immunol*. 2020:1–9. doi:10.1159/000509057.
95. Cancer. Fact sheets. Geneva: World Health Organization; 2020 (<https://www.who.int/news-room/fact-sheets/detail/cancer>, accessed 16 July 2020).
96. Brissot E, Labopin M, Baron F, Bazarbachi A, Bug G, Ciceri F, et al. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2020:1–4. doi:10.1038/s41409-020-0970-x.
97. Yeoh CB, Lee KJ, Rieth EF, Mapes R, Tchoudovskaia AV, Fischer GW, et al. COVID-19 in the cancer patient. *Anesth Analg*. 2020:1-8. doi:10.1213/ane.0000000000004884.
98. Dai M, Liu D, Liu M, Zhou F, Li G, Zhen C, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. *Cancer Discov*. 2020;10(6):783–91.
99. Desai A, Sachdeva S, Parekh T, Desai R. Covid-19 and cancer: lessons from a pooled meta-analysis. *JCO Glob Oncol*. 2020;6(6):557–9.
100. Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. *Lancet Oncol*. 2020;21(7):893.
101. Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. *J Hematol Oncol*. 2020;13(1):75.
102. Robinson AG, Gyawali B, Evans G. COVID-19 and cancer: Do we really know what we think we know? *Nat Rev Clin Oncol*. 2020:1–6. doi:10.1038/s41571-020-0394-y.
103. Demaio A, Jamieson J, Horn R, De Courten M, Tellier S. Non-communicable diseases in emergencies: A call to action. *PLoS Currents Disasters*. 2013;5. doi:10.1371/currents.dis.53e08b951d59ff913ab8b9bb51c4d0de.
104. Parpia AS, Ndeffo-Mbah ML, Wenzel NS, Galvani AP. Effects of response to 2014–2015 Ebola outbreak on deaths from malaria, HIV/AIDS, and tuberculosis, West Africa. *Emerg Infect Dis*. 2016;22(3):433–41.
105. Ribacke KJB, Saulnier DD, Eriksson A, von Schreeb J. Effects of the West Africa Ebola virus disease on health-care utilization – a systematic review. *Front Public Health*. 2016;4(10):222.
106. Elston JWT, Cartwright C, Ndumbi P, Wright J. The health impact of the 2014–15 Ebola outbreak. *Public Health*. 2017;143:60–70.
107. Rapid assessment of service delivery for NCDs during the COVID-19 pandemic. Geneva: World Health Organization; 2020 (<https://www.who.int/publications/m/item/rapid-assessment-of-service-delivery-for-ncds-during-the-covid-19-pandemic>, accessed 16 June 2020).
108. Safe route to care – primary health center redesign during the COVID-19 pandemic. Washington DC: Resolve To Save Lives; 2020 ([https://linkscommunity.org/assets/PDFs/cov069\\_primaryhealthcenterredesign\\_v3\\_final.pdf](https://linkscommunity.org/assets/PDFs/cov069_primaryhealthcenterredesign_v3_final.pdf), accessed 21 May 2020).
109. Rapid assessment of continuity of essential health services (EHS) during the COVID-19 pandemic. Geneva: World Health Organization; 2020. In press.

